XI'AN, CHINA--(Marketwire - August 24, 2009) - Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"), a China-based producer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today announced that the Company has begun manufacturing on a series of 18 new veterinary products and additives designed to prevent epidemics and treat poultry diseases for large scale breeding farms. The new SkyWing Series products improves egg laying and hatching rates, enhances feed conversion ratios, heals immune deficiencies, improves growth rates for turkeys and chickens, protect poultry from colibacillosis and other bacteria and virus infections. Skystar expects to begin distributing its new SkyWing Series of products to its diverse customer base by the end of the third quarter of 2009.

"The introduction of our SkyWing Series expands our veterinary medication product line to address the large and underserved poultry health and nutrition market in China, which represents an estimated US$3 million market opportunity," said Weibing Lu, Skystar's Chairman and Chief Executive Officer. "Our SkyWing Series offers significant benefits compared with currently marketed products. SkyWing products, when compared with our competitors, are safer for the animal, are more efficient and have better drug absorption and prevent to incur drug resistance. We expect this important product series to account for a material portion of our revenue beginning in the fourth quarter of 2009."

Leveraging Skystar's advanced veterinary and medical care technologies, the SkyWing Series products are uniquely formulated to resist oxidation while providing an extremely high curative effect. SkyStar has been developing its SkyWing Series of products since 2008. Including the SkyWing Series, SkyStar now markets over 70 products that address poultry health and nutrition.

About Skystar Bio-Pharmaceutical Company

Skystar is a China-based developer and distributor of veterinary healthcare and medical care products. Skystar has four product lines (veterinary medicines, micro-organisms, vaccines and feed additives) and over 170 products, with over 40 additional products in the developmental stage. Skystar has formed strategic sales distribution networks covering 29 provinces throughout China. For additional information, please visit http://www.skystarbio-pharmaceutical.com.

To be added to the Company's email distribution for future news releases, please send your request to skystar@tpg-ir.com.

Forward-looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: Certain of the statements made in the press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.